Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Liabilities and Shareholders Equity (2009 - 2025)

Grifols' (GIFLF) quarterly Liabilities and Shareholders Equity came in at $22.9 billion in Q4 2025, little changed on a YoY basis from $22.9 billion in Q4 2024, and little changed quarter-over-quarter from $22.9 billion in Q4 2024.

Analysis

Grifols (GIFLF) Liabilities and Shareholders Equity (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $22.9 billion the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity changed 0.32% year-over-year to $22.9 billion; the trailing twelve-month figure through Dec 2025 stood at $90.1 billion (up 19.31% YoY), and the FY2025 full-year result was $22.3 billion, down 2.63% from the prior year.
  • Liabilities and Shareholders Equity was little changed at $22.9 billion in Q4 2025 per GIFLF's latest filing, from $22.9 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $22.9 billion in Q4 2025 and bottomed at $8.4 billion in Q4 2021.
  • Historically, Liabilities and Shareholders Equity has averaged $19.7 billion across 5 years, with a median of $22.6 billion in 2023.
  • The sharpest annual moves came in 2021 and 2022: Liabilities and Shareholders Equity tumbled 54.04% in 2021, then jumped 158.76% in 2022.
  • Over 5 years, Liabilities and Shareholders Equity stood at $8.4 billion in 2021, then surged by 158.76% to $21.7 billion in 2022, then gained by 4.28% to $22.6 billion in 2023, then grew by 1.27% to $22.9 billion in 2024, then grew by 0.32% to $22.9 billion in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $22.9 billion, $22.9 billion, and $22.6 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 95.64 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 49.36 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 27.42 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 41.73 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 10.03 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 10.96 Bn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 5.56 Bn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 32.09 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn 5.31 Bn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 22.95 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 22.95 Bn
Dec 31, 2024 22.87 Bn
Dec 31, 2023 22.59 Bn
Dec 31, 2022 21.66 Bn
Dec 31, 2021 8.37 Bn
Dec 31, 2020 18.21 Bn
Sep 30, 2020 18.28 Bn
Mar 31, 2020 17.55 Bn
Dec 31, 2019 17.20 Bn
Sep 30, 2019 15.62 Bn
Mar 31, 2019 15.22 Bn
Dec 31, 2018 14.24 Bn
Sep 30, 2018 13.70 Bn
Jun 30, 2018 13.65 Bn
Mar 31, 2018 16.45 Bn
Dec 31, 2017 12.86 Bn
Jun 30, 2017 12.22 Bn
Dec 31, 2016 10.94 Bn
Sep 30, 2016 10.68 Bn
Jun 30, 2016 10.78 Bn